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Introduction of stem cell-based therapies in the past decade has opened a new treatment options for many disease and clinical conditions where standard therapies have either failed or were ineffective [2] . Fecal incontinence (FI) represents a challenging clinical and healthcare problem. Current methods of treatment both conservative, including pharmacotherapy, biofeedback, silicone elastomer prosthesis (Acticon Neosphincter TM ) [3] , as well as radio-frequency energy delivery, and surgical such as sphinctotherapy are not optimal, and long-term results are not satisfactory [4] .
This creates a significant medical and social problem in large population of patients with fecal incontinence and affects their daily leaving activities and quality of life. In addition, the financial burden to treat FI as well as related complications is substantial and exceeds $4000 per year in both Europe and the USA [5] .
Thus, there is an urgent need to search for new methods and approaches to treat fecal incontinence. Several innovative approaches have been proposed and tested including new devices, pharmacological agents, new biofeedback programs, and sacral and posterior tibial nerve stimulation. However, none of these approaches became a standard of care; thus, the stem cell-based therapies seem to have the best therapeutic potential.
Several investigators have published promising results using stem cell therapies in experimental models of incontinent rodents and mongrel dogs [6, 7] . On the basis of existing data, local myoblast [8] and intravenous MSC therapies [9] have achieved the best results.
There are numerous reports on clinical application of myoblasts and MSC in treatment of urinary incontinence and muscular dystrophies [10, 11] . Limited data are available with regard to cell therapies in FI patients even though already published results are encouraging [12] .
The clinical study of Romaniszyn et al. is representing an innovative approach to treat FI with autologous myoblasts. This pilot prospective experimental clinical trial was approved by appropriate ethical committees and is summarizing the outcomes of ten patients with FI enrolled into the study and treated with autologous muscle-derived stem cells. The standard methods of assessment were employed, including Incontinence Severity Index (ISI) questionnaire, anorectal manometry, surface endoanal electromyography, endorectal ultrasound, and clinical examination. Nine patients were followed up to 12 months. Overall, functional tests confirmed that myoblast stem cell therapy improved continence in 4 patients (44.4 %).
This pilot study on a small group of patients has several limitations that were raised by the authors in the Discussion section of the article. These include sparse cohort, dispersal of the patients' age, short follow-up, postoperative evaluation by means of subjective questionnaire, and postimplantational edema that may be responsible for a ''placebo effect.'' Furthermore, this method can be applied only in patients with undamaged sphincter innervation. The description of method of myoblast transplantation including clear outline of sites of implantation procedure as well as the number of cells used per injection is helpful for investigators interested in using this approach for treatment of fecal incontinence. This will allow to compare results generated by different centers and will support application of this therapy as a standard of care in the near future.
The most important points which have to be emphasized include results which confirm that the therapy was safe and no complications were reported after cell injection. Romaniszyn and his team applied well-investigated model that proved to be effective in using myoblasts for treatment of different muscle disorders, since the first trials in the late 1970s [13] . In addition, it has to be emphasized that application of autologous cells does not generate immune response and thus is safer compared with allogenic cells application which requires immunosuppression and exposes patients to its harmful side effects. Besides subjective questionnaire, investigators applied more objective methods to assess sphincter performance, including anorectal manometry, surface endorectal EMG, and ERUS. Myoblast activity was confirmed, using surface electromyography rectal probe.
Since the results of the study are encouraging, it will be important that this pilot trial serves as the basis for a clinical trial with a larger cohort of patients and with defined inclusion and exclusion criteria. In addition, therapy kinetics, including stem cell number and timing of cell delivery, has to be still established.
In summary, the authors have to be congratulated on the conducted clinical study using myoblast stem cell therapy as an innovative approach to treat fecal incontinence. Once the stem cell protocol is defined and its therapeutic effect confirmed in a large population of patients with fecal incontinence, this method may become a standard of care helping many patients who are currently suffering from this socially withdrawing clinical condition.
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